Migration-stimulating factor as a novel biomarker in salivary gland tumours

Lateef E. Aljorani, Agnes Bankfalvi, Frank A. Carey, Koji Harada, Go Ohe, Sarah J. Jones, Ian R. Ellis, Seth L. Schor, Ana M. Schor

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    BACKGROUND: The identification of novel stratification biomarkers would benefit the clinical management of patients with salivary gland tumours. Migration-stimulating factor (MSF) is a potent stimulator of cell invasion, matrix remodelling and angiogenesis. The aim of this study was to determine whether MSF was expressed in salivary gland tumours and its potential value as a diagnostic biomarker.

    METHODS: Paraffin-embedded archival specimens of small salivary gland tumours were stained with an MSF-specific antibody. The specimens included 27 malignant and seven benign tumours; histologically normal salivary gland adjacent to the tumour was present in 16 specimens. MSF expression was assessed by consensus of 2-4 independent observers according to various indices, including 'overall MSF grade', 'percentage of area stained' and 'intensity of the staining'. The motogenic effect of MSF on a salivary gland tumour cell line, HSG, was examined in the transmembrane assay.

    RESULTS: Overall MSF expression increased significantly in a step-wise fashion from normal salivary gland to benign and malignant tumours (P = 0.04-0.0001); with moderate/strong positive specimens representing 6%, 33% and 74% of the normal, benign and malignant specimens, respectively. MSF was heterogeneously expressed in both carcinoma and stromal cell compartments, its expression being higher in malignant than benign tumours regarding various MSF indices. In tissue culture studies, exogenous MSF stimulated the migration of HSG cells.

    CONCLUSIONS: These immunohistochemical and functional studies suggest that MSF expression is a potentially useful biomarker of salivary gland tumour progression.

    Original languageEnglish
    Pages (from-to)747-754
    Number of pages8
    JournalJournal of Oral Pathology and Medicine
    Volume40
    Issue number10
    DOIs
    Publication statusPublished - Nov 2011

    Keywords

    • benign tumours
    • cancer
    • disease progression
    • MSF
    • salivary gland tumours
    • ENDOTHELIAL-CELLS
    • ANGIOGENESIS
    • FIBRONECTIN
    • FIBROBLASTS
    • EXPRESSION
    • CARCINOMA

    Cite this

    Aljorani, Lateef E. ; Bankfalvi, Agnes ; Carey, Frank A. ; Harada, Koji ; Ohe, Go ; Jones, Sarah J. ; Ellis, Ian R. ; Schor, Seth L. ; Schor, Ana M. / Migration-stimulating factor as a novel biomarker in salivary gland tumours. In: Journal of Oral Pathology and Medicine. 2011 ; Vol. 40, No. 10. pp. 747-754.
    @article{ca4bcfb553dd4304b0c259cfb7bc7677,
    title = "Migration-stimulating factor as a novel biomarker in salivary gland tumours",
    abstract = "BACKGROUND: The identification of novel stratification biomarkers would benefit the clinical management of patients with salivary gland tumours. Migration-stimulating factor (MSF) is a potent stimulator of cell invasion, matrix remodelling and angiogenesis. The aim of this study was to determine whether MSF was expressed in salivary gland tumours and its potential value as a diagnostic biomarker.METHODS: Paraffin-embedded archival specimens of small salivary gland tumours were stained with an MSF-specific antibody. The specimens included 27 malignant and seven benign tumours; histologically normal salivary gland adjacent to the tumour was present in 16 specimens. MSF expression was assessed by consensus of 2-4 independent observers according to various indices, including 'overall MSF grade', 'percentage of area stained' and 'intensity of the staining'. The motogenic effect of MSF on a salivary gland tumour cell line, HSG, was examined in the transmembrane assay.RESULTS: Overall MSF expression increased significantly in a step-wise fashion from normal salivary gland to benign and malignant tumours (P = 0.04-0.0001); with moderate/strong positive specimens representing 6{\%}, 33{\%} and 74{\%} of the normal, benign and malignant specimens, respectively. MSF was heterogeneously expressed in both carcinoma and stromal cell compartments, its expression being higher in malignant than benign tumours regarding various MSF indices. In tissue culture studies, exogenous MSF stimulated the migration of HSG cells.CONCLUSIONS: These immunohistochemical and functional studies suggest that MSF expression is a potentially useful biomarker of salivary gland tumour progression.",
    keywords = "benign tumours, cancer, disease progression, MSF, salivary gland tumours, ENDOTHELIAL-CELLS, ANGIOGENESIS, FIBRONECTIN, FIBROBLASTS, EXPRESSION, CARCINOMA",
    author = "Aljorani, {Lateef E.} and Agnes Bankfalvi and Carey, {Frank A.} and Koji Harada and Go Ohe and Jones, {Sarah J.} and Ellis, {Ian R.} and Schor, {Seth L.} and Schor, {Ana M.}",
    note = "{\circledC} 2011 John Wiley & Sons A/S.",
    year = "2011",
    month = "11",
    doi = "10.1111/j.1600-0714.2011.01044.x",
    language = "English",
    volume = "40",
    pages = "747--754",
    journal = "Journal of Oral Pathology and Medicine",
    issn = "0904-2512",
    publisher = "Wiley",
    number = "10",

    }

    Aljorani, LE, Bankfalvi, A, Carey, FA, Harada, K, Ohe, G, Jones, SJ, Ellis, IR, Schor, SL & Schor, AM 2011, 'Migration-stimulating factor as a novel biomarker in salivary gland tumours', Journal of Oral Pathology and Medicine, vol. 40, no. 10, pp. 747-754. https://doi.org/10.1111/j.1600-0714.2011.01044.x

    Migration-stimulating factor as a novel biomarker in salivary gland tumours. / Aljorani, Lateef E.; Bankfalvi, Agnes; Carey, Frank A.; Harada, Koji; Ohe, Go; Jones, Sarah J.; Ellis, Ian R.; Schor, Seth L.; Schor, Ana M.

    In: Journal of Oral Pathology and Medicine, Vol. 40, No. 10, 11.2011, p. 747-754.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Migration-stimulating factor as a novel biomarker in salivary gland tumours

    AU - Aljorani, Lateef E.

    AU - Bankfalvi, Agnes

    AU - Carey, Frank A.

    AU - Harada, Koji

    AU - Ohe, Go

    AU - Jones, Sarah J.

    AU - Ellis, Ian R.

    AU - Schor, Seth L.

    AU - Schor, Ana M.

    N1 - © 2011 John Wiley & Sons A/S.

    PY - 2011/11

    Y1 - 2011/11

    N2 - BACKGROUND: The identification of novel stratification biomarkers would benefit the clinical management of patients with salivary gland tumours. Migration-stimulating factor (MSF) is a potent stimulator of cell invasion, matrix remodelling and angiogenesis. The aim of this study was to determine whether MSF was expressed in salivary gland tumours and its potential value as a diagnostic biomarker.METHODS: Paraffin-embedded archival specimens of small salivary gland tumours were stained with an MSF-specific antibody. The specimens included 27 malignant and seven benign tumours; histologically normal salivary gland adjacent to the tumour was present in 16 specimens. MSF expression was assessed by consensus of 2-4 independent observers according to various indices, including 'overall MSF grade', 'percentage of area stained' and 'intensity of the staining'. The motogenic effect of MSF on a salivary gland tumour cell line, HSG, was examined in the transmembrane assay.RESULTS: Overall MSF expression increased significantly in a step-wise fashion from normal salivary gland to benign and malignant tumours (P = 0.04-0.0001); with moderate/strong positive specimens representing 6%, 33% and 74% of the normal, benign and malignant specimens, respectively. MSF was heterogeneously expressed in both carcinoma and stromal cell compartments, its expression being higher in malignant than benign tumours regarding various MSF indices. In tissue culture studies, exogenous MSF stimulated the migration of HSG cells.CONCLUSIONS: These immunohistochemical and functional studies suggest that MSF expression is a potentially useful biomarker of salivary gland tumour progression.

    AB - BACKGROUND: The identification of novel stratification biomarkers would benefit the clinical management of patients with salivary gland tumours. Migration-stimulating factor (MSF) is a potent stimulator of cell invasion, matrix remodelling and angiogenesis. The aim of this study was to determine whether MSF was expressed in salivary gland tumours and its potential value as a diagnostic biomarker.METHODS: Paraffin-embedded archival specimens of small salivary gland tumours were stained with an MSF-specific antibody. The specimens included 27 malignant and seven benign tumours; histologically normal salivary gland adjacent to the tumour was present in 16 specimens. MSF expression was assessed by consensus of 2-4 independent observers according to various indices, including 'overall MSF grade', 'percentage of area stained' and 'intensity of the staining'. The motogenic effect of MSF on a salivary gland tumour cell line, HSG, was examined in the transmembrane assay.RESULTS: Overall MSF expression increased significantly in a step-wise fashion from normal salivary gland to benign and malignant tumours (P = 0.04-0.0001); with moderate/strong positive specimens representing 6%, 33% and 74% of the normal, benign and malignant specimens, respectively. MSF was heterogeneously expressed in both carcinoma and stromal cell compartments, its expression being higher in malignant than benign tumours regarding various MSF indices. In tissue culture studies, exogenous MSF stimulated the migration of HSG cells.CONCLUSIONS: These immunohistochemical and functional studies suggest that MSF expression is a potentially useful biomarker of salivary gland tumour progression.

    KW - benign tumours

    KW - cancer

    KW - disease progression

    KW - MSF

    KW - salivary gland tumours

    KW - ENDOTHELIAL-CELLS

    KW - ANGIOGENESIS

    KW - FIBRONECTIN

    KW - FIBROBLASTS

    KW - EXPRESSION

    KW - CARCINOMA

    U2 - 10.1111/j.1600-0714.2011.01044.x

    DO - 10.1111/j.1600-0714.2011.01044.x

    M3 - Article

    VL - 40

    SP - 747

    EP - 754

    JO - Journal of Oral Pathology and Medicine

    JF - Journal of Oral Pathology and Medicine

    SN - 0904-2512

    IS - 10

    ER -